In conclusion, loss of ACVR2, ACVR1 and pSMAD2 expression occurs in a subset of MSS tumors, and the evidence supports that this results in abrogation of the normal growth suppressive activity of activin signaling. This evidence concerns the gene ACVR2A and Marinesco-Sjogren syndrome.